Importantly, pharmacological or genetic inhibition of PI3K/AKT/mTOR rescues the aggressive phenotypes induced by ARF6 overexpression, establishing this pathway as a critical mediator of ARF6's oncogenic effects in AML. Here, AKT1 is linked to acute myeloid leukemia.